Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9744375 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL4328796 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL9744380 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL2712968 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| Hydrochloric Acid SCHEMBL30546580 | 0.98 | TSHR (0.36) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL5131640 | 0.98 | BTK (0.36) | TSHRBTKGAAKMT2A | |
| SCHEMBL4996407 | 0.98 | BTK (0.36) | TSHRBTKGAAKMT2A | |
| SCHEMBL3672475 | 0.97 | BTK (0.36) | TSHRBTKKMT2A | |
| SCHEMBL2350718 | 0.92 | KMT2A (0.34) | BTKGAAKMT2A | |
| SCHEMBL2350728 | 0.92 | KMT2A (0.34) | BTKGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118845947-B | Preparation process of dendrobium candidum composite particles for clearing liver and improving eyesight | 江西省中医药研究院 | 2025-05-13 | — | — | CN | claimed |
| CN-118845947-A | Preparation process of dendrobium candidum composite particles for clearing liver and improving eyesight | 江西省中医药研究院 | 2024-10-29 | — | — | CN | claimed |
| CN-104910039-A | Functional phenylacetylene compound and preparation method thereof | UNIV HARBIN ENG | 2015-09-16 | — | — | CN | claimed |
| US-20070249526-A1 | PROCESS FOR THE PREPARATION OF CYCLIC PEPTIDES | ABBENANTE GIOVANNI | 2007-10-25 | — | — | US | claimed |
| US-20050119167-A1 | Process for the preparation of cyclic peptides | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-06-02 | — | — | US | claimed |
| US-12636275-B2 | Pharmaceutical use of ketoamide-based compound | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-26 | — | — | US | disclosed |
| CN-118845947-B | Preparation process of dendrobium candidum composite particles for clearing liver and improving eyesight | 江西省中医药研究院 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025032242-A1 | COMPOUNDS AND USES | UNIVERSITEIT LEIDEN (NL) | 2025-02-13 | — | — | WO | disclosed |
| US-12152017-B2 | Ketoamide compound and preparation method, pharmaceutical composition, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-11-26 | — | — | US | disclosed |
| CN-118845947-A | Preparation process of dendrobium candidum composite particles for clearing liver and improving eyesight | 江西省中医药研究院 | 2024-10-29 | — | — | CN | disclosed |
| US-11932628-B2 | Selective small molecule peptidomimetic melanocortin ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-03-19 | — | — | US | disclosed |
| CN-114933626-B | Ginsenoside Rb 1 Derivatives and uses thereof | 云南大学 | 2024-02-09 | — | — | CN | disclosed |
| US-4485099-A | HYPOTENSIVE AGENTS/,ANTIALDOSTERONES | MERCK & CO., INC. (US) | 1984-11-27 | — | — | US | disclosed |
| US-4479941-A | TREATMENT OF HYPERTENSION AND HYPERALDOSTERONISM | MERCK & CO., INC. (US) | 1984-10-30 | — | — | US | disclosed |
| US-4477441-A | HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1984-10-16 | — | — | US | disclosed |
| US-4477440-A | HYPERTENSIVE AGENTS; HYPERALDOSTERONISM; MEDICAL DIAGNOSIS; CYCLIC POLYPEPTIDES | MERCK & CO., INC. (US) | 1984-10-16 | — | — | US | disclosed |
| EP-0114993-A2 | Renin inhibitory tripeptides | MERCK & CO. INC. (US) | 1984-08-08 | — | — | EP | disclosed |
| EP-0081783-A1 | Renin inhibitory peptides having Phe 13 deletion | MERCK & CO. INC. (US) | 1983-06-22 | — | — | EP | disclosed |
| US-4199501-A | INHIBITORS OF SECRETION OF GROWTH HORMONE | ELI LILLY AND COMPANY (US) | 1980-04-22 | — | — | US | disclosed |
| US-4061607-A | Somatostatin analogs and intermediates thereto | ELI LILLY AND COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932628-B2 | Selective small molecule peptidomimetic melanocortin ligands | MC1R, MC3R, MC4R | TSHR 96/4885BTK 844/4885GAA 4676/4885 |
| US-20050119167-A1 | Process for the preparation of cyclic peptides | C3AR1, C5AR1, C9 | TSHR 2661/4885BTK 3731/4885GAA 4826/4885 |
| US-20070249526-A1 | PROCESS FOR THE PREPARATION OF CYCLIC PEPTIDES | C3AR1, C5AR1, C9 | TSHR 2661/4885BTK 3731/4885GAA 4826/4885 |
| US-12636275-B2 | Pharmaceutical use of ketoamide-based compound | CTSV, CTSL, CTSS | TSHR 2450/4885BTK 3136/4885GAA 427/4885 |
| US-12152017-B2 | Ketoamide compound and preparation method, pharmaceutical composition, and use thereof | ACE, REN, ACE2 | TSHR 3993/4885BTK 3470/4885GAA 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.